Difference between revisions of "Alectinib (Alecensa)"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism | + | Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK). Alectinib and its metabolite M4 inhibit ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, which results in decreased growth of tumor cells which have ALK fusions, amplifications, or activating mutations.<ref name=insert>[http://www.gene.com/download/pdf/alecensa_prescribing.pdf Alectinib (Alecensa) package insert]</ref><ref>[[Media:Alectinib.pdf|Alectinib (Alecensa) package insert (locally hosted backup)]]</ref><ref>[http://alecensa.com/ Alecensa manufacturer's website]</ref><ref>[http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=733572 Alectinib entry at the NCI Drug Dictionary]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 10: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://www.gene.com/download/pdf/alecensa_prescribing.pdf Alectinib (Alecensa) package insert]<ref name="insert"></ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *12/11/2015: Granted accelerated FDA approval "for the treatment of patients with [[Non-small_cell_lung_cancer|anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)]] who have progressed on or are intolerant to [[Crizotinib (Xalkori)|crizotinib]]." | + | *12/11/2015: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm476946.htm Granted accelerated FDA approval] "for the treatment of patients with [[Non-small_cell_lung_cancer|anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)]] who have progressed on or are intolerant to [[Crizotinib (Xalkori)|crizotinib]]." |
==Also known as== | ==Also known as== | ||
| − | AF802, AF-802, CH5424802, RG7853, RO5424802, UNII-LIJ4CT1Z3Y | + | *AF802, AF-802, CH5424802, RG7853, RO5424802, UNII-LIJ4CT1Z3Y |
==References== | ==References== | ||
| + | <references/> | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
Revision as of 07:07, 12 December 2015
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK). Alectinib and its metabolite M4 inhibit ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, which results in decreased growth of tumor cells which have ALK fusions, amplifications, or activating mutations.[1][2][3][4]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 12/11/2015: Granted accelerated FDA approval "for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib."
Also known as
- AF802, AF-802, CH5424802, RG7853, RO5424802, UNII-LIJ4CT1Z3Y